New Study Suggests CytoSorb Improves Clinical Outcomes in Pneumonia Patients With Septic Shock and Acute Respiratory Distress Syndrome (ARDS) on

New Study Suggests CytoSorb Improves

Clinical Outcomes in Pneumonia Patients With Septic Shock and Acute Respiratory Distress Syndrome (ARDS) on ECMO

MONMOUTH JUNCTION, N.J., April 15, 2020

-- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb

blood purification technology to treat cytokine storm and deadly inflammation in critically-ill and cardiac surgery patients around

the world, highlights a recently published study entitled, "Combined Use of CytoSorb and ECMO in Patients with Severe

Pneumogenic Sepsis" in the medical journal, The Thoracic and Cardiovascular Surgeon.

In this prospective study, Akil

and colleagues compared the clinical outcomes of 13 critically-ill pneumonia patients with severe acute respiratory distress syndrome

(ARDS; P/F <100) on extracorporeal membrane oxygenation (ECMO), septic shock requiring high levels of the vasopressor norepinephrine,

and a lactate concentration of 2.0 mmol/L, who were treated with CytoSorb, with a comparable historical cohort of 7 patients that

did not use CytoSorb. The cause of pneumonia in the CytoSorb group was influenza in 3 patients, bacterial in 9 patients, and fungal

in one patient. CytoSorb was started simultaneously with ECMO within 6 hours after admission to the ICU and within 12 hours of

sepsis diagnosis. CytoSorb was integrated into a bypass circuit in the ECMO machine, and changed every 24 hours. All patients

received at least 2 cartridges, and a maximum of three. Blood flow rates were between 200-400 mL/min.

The use of CytoSorb with ECMO was associated

with a shorter mean duration on ECMO of 8.2 days (range: 2-23 days) vs 26.5 days (range: 13-30 days) in the control, a rapid reversal

of septic shock within 48 hours, and a marked decrease in lactate and inflammatory markers. Despite the higher expected ICU mortality

in the CytoSorb group based on the median Simplified Acute Physiology Score II (SAPS II) at admission to the ICU of 58.2 (range:

49-66; predicted mortality of ~60%) compared with 50.2 (range: 42-55; predicted mortality of ~50%) in the control group, there

were no deaths at 30 days in the CytoSorb treated group, compared to 57% 30-day mortality in the control. Mean ICU stay was not

different, but may reflect survival bias. There were no adverse events related to the treatment or adsorber.

Dr. Phillip Chan, MD, PhD, Chief Executive

Officer of CytoSorbents stated, "Although there are limitations in interpreting a small study such as this, the 13 patients

who were prospectively enrolled into the study and received CytoSorb treatment did remarkably well, despite being critically-ill,

with multi-organ failure, and a high risk of death. In these patients, CytoSorb was associated with a rapid weaning from ECMO,

a reversal of septic shock, a reduction in inflammatory mediators, and most importantly, 100% survival. The key difference between

this study and other published ECMO studies, including those done with CytoSorb, is the early combined intervention with both ECMO

and CytoSorb, combined with lung protective ventilation that allows the lungs to rest and heal."

Dr. Chan continued, "Meanwhile,

the publication of this study is very timely, as it coincides with the COVID-19 pandemic, where roughly half of

critically-ill patients die in the ICU. The main cause of death is respiratory failure and acute respiratory distress

syndrome (ARDS), where approximately two thirds of patients die who required advanced respiratory support, including

mechanical ventilation and ECMO. In addition, up to 30% of COVID-19 patients also have septic shock. Given the large number

of COVID-19 patients on ECMO, and the strong results seen in this ECMO study, we will seek to leverage our new insight to

help these patients. CytoSorb is being used to treat COVID-19 patients in many countries all over the world, and with our

recent FDA Emergency Use Authorization of CytoSorb in the U.S., we are excited to bring this technology to help treat

patients here at home."

Severe bacterial or viral pneumonia, as

seen in influenza or COVID-19 infection, can trigger sepsis and a damaging cytokine storm that directly injures the integrity of

blood vessels in the lung, allowing inflammatory fluid and cells to leak into the air spaces of the lung. Lung failure can ensue,

requiring mechanical ventilation, which can inadvertently exacerbate lung injury through oxygen toxicity and the trauma of forcing

air into the lungs. As severe acute respiratory distress syndrome (ARDS) worsens, gas exchange can become so compromised that the

patient may die from a global lack of oxygen. Extracorporeal membrane oxygenation (ECMO), a machine that can oxygenate blood outside

the body, is used increasingly to salvage patients with ARDS while allowing the lungs to rest on nominal ventilator settings. However,

ECMO does not reduce the cytokine storm that causes continued lung injury and prevents healing. In addition, these patients are

often so critically-ill with other organ failure that recovery is long, with a high expected mortality. For this reason, CytoSorb

has been used in conjunction with ECMO in thousands of treatments, as a combined therapy to help improve clinical outcomes in these

About CytoSorbents Corporation (NASDAQ:

CytoSorbents Corporation is

a leader in critical care immunotherapy, specializing in blood purification. Its flagship product, CytoSorb is approved

in the European Union with distribution in 58 countries around the world, as an extracorporeal cytokine adsorber designed to reduce

the "cytokine storm" or "cytokine release syndrome" that could otherwise cause massive inflammation, organ

failure and death in common critical illnesses. These are conditions where the risk of death is extremely high, yet no effective

treatments exist. CytoSorb has been used in more than 80,000 human treatments to date. CytoSorb has received FDA Emergency

Use Authorization in the United States for use in critically-ill COVID-19 patients with imminent or confirmed respiratory

failure, in defined circumstances.

CytoSorbents' purification technologies

are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily

fluids by pore capture and surface adsorption. Its technologies have received non-dilutive grant, contract, and other funding

of nearly $29 million from DARPA, the U.S. Army, the U.S. Department of Health and Human Services, the National Institutes of

Health (NIH), National Heart, Lung, and Blood Institute (NHLBI), U.S. Special Operations Command (SOCOM), the U.S. Army,

U.S. Special Operations Command (USSOCOM), the U.S. Air Force, Air Force Material Command (USAF/AFMC) and others. The Company

has numerous products under development based upon this unique blood purification technology protected by many issued U.S. and

international patents and multiple applications pending, including CytoSorb-XL , HemoDefend , VetResQ , K+ontrol ,

ContrastSorb, DrugSorb, and others. For more information, please visit the Company's websites at www.cytosorbents.com and

Forward-Looking Statements

This press release includes forward-looking

statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of

1995. These forward-looking statements include, but are not limited to, statements about our plans, objectives, representations

and contentions and are not historical facts and typically are identified by use of terms such as "may," "should,"

"could," "expect," "plan," "anticipate," "believe," "estimate," "predict,"

"potential," "continue" and similar words, although some forward-looking statements are expressed differently.

You should be aware that the forward-looking statements in this press release represent management's current judgment and expectations,

but our actual results, events and performance could differ materially from those in the forward-looking statements. Factors which

could cause or contribute to such differences include, but are not limited to, the risks discussed in our Annual Report on Form

10-K, filed with the SEC on March 5, 2020, as updated by the risks reported in our Quarterly Reports on Form 10-Q, and in

the press releases and other communications to shareholders issued by us from time to time which attempt to advise interested parties

of the risks and factors which may affect our business. We caution you not to place undue reliance upon any such forward-looking

statements, particularly in light of the current coronavirus pandemic, where businesses can be impacted by rapidly changing state

and federal regulations, as well as the health and availability of their workforce. We undertake no obligation to publicly update

or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, other than as required

under the Federal securities laws.

CytoSorbents Contact:

Investor Relations Contact:

Public Relations Contact:

Rubenstein Public Relations

SOURCE CytoSorbents Corporation